Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP8 | P40818 | 2/20 | 0.58 |
| ▸ | USP7 | Q93009 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31289519 | 0.92 | USP8 (0.58) | USP8USP7MEN1KMT2ACDC25B | |
| SCHEMBL939194 | 0.92 | USP8 (0.58) | USP8USP7MEN1KMT2ACDC25B | |
| Methane SCHEMBL27726276 | 0.90 | USP8 (0.56) | USP8USP7MEN1KMT2ACDC25B | |
| SCHEMBL31112601 | 0.85 | USP8 (0.51) | USP8USP7MEN1KMT2ACDC25B | |
| SCHEMBL8486849 | 0.85 | USP8 (0.48) | USP8USP7MEN1KMT2AADORA2A | |
| SCHEMBL9265082 | 0.84 | USP8 (0.58) | USP8USP7MEN1KMT2ACDC25B | |
| SCHEMBL5576916 | 0.83 | MEN1 (0.50) | USP8USP7MEN1KMT2ACA1 | |
| SCHEMBL2567528 | 0.83 | MEN1 (0.50) | USP8USP7MEN1KMT2ACA1 | |
| SCHEMBL5520687 | 0.82 | MEN1 (0.50) | USP8USP7MEN1KMT2ACDC25B | |
| SCHEMBL11076090 | 0.81 | ESR2 (0.52) | USP8USP7MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CALASIA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CALASIA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20210154213-A1 | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES | CALASIA PHARMACEUTICALS INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-5434264-A | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5300642-A | α, α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0311010-B1 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | DU PONT MERCK PHARMA (US) | 1994-02-02 | — | — | EP | disclosed |
| EP-0532054-A1 | Process for preparing alpha,alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5173489-A | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DUPONT MERCK PHARMACEUTICAL CO. (US) | 1992-12-22 | — | — | US | disclosed |
| EP-0311010-A2 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154213-A1 | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES | CRYAA, CRYAB, TTR | USP8 2743/4885USP7 2322/4885MEN1 3695/4885 |
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CRYAA, CRYAB, TTR | USP8 2743/4885USP7 2322/4885MEN1 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.